Global stocks hit a new record high on Monday as positive data
for a potential COVID-19 vaccine came from Moderna, following
similarly upbeat data from rival Pfizer. Investors surveyed by
BofA expect a "credible vaccine" by January.
The euphoria sent investors' cash levels down to 4.1% in
November, from 4.4% last month, to pre-COVID-19 levels last seen
in January, according to the survey of 190 fund managers with
$526 billion in assets under management.
With global economic growth and profit expectations running at a
20-year high among the investors surveyed, the "reopening
rotation" into oversold business sectors is likely to continue
in the fourth quarter, BofA said.
But the bank advised clients: "We say 'sell the vaccine' in
coming weeks/months as we think we're close to 'full bull'."
Meanwhile, in U.S. Treasuries, 73% of the investors surveyed
were expecting steeper yield curves -- rates on longer-term U.S.
Treasury securities rising faster than short-term rates.
Expectations were far higher than after the 2008 Lehman
bankruptcy, 2013 taper tantrum and 2016 elections.
For 2021, investors named "long" emerging market assets, S&P 500
<.SPX> and oil as their favourite trades. Nearly half of the
investors surveyed by BofA said they expect emerging markets to
outperform in 2021.
Graphic: Global stocks -
https://fingfx.thomsonreuters.com/
gfx/buzz/gjnvwbjeepw/Pasted%20image%201605604723061.png
(Reporting by Thyagaraju Adinarayan; editing by Sujata Rao and
Ed Osmond)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|